FindTrial
Sign In

Comparison of oral tamsulosin with oral tamsulosin and oral isosorbide dinitrate with in improvements trial without catheter (TWOC) for patients with acute urinary retention due to benign prostatic hyperplasia (BPH)

Comparison of oral tamsulosin with oral tamsulosin and oral isosorbide dinitrate with in improvements trial without catheter (TWOC) for patients with acute urinary retention due to benign prostatic hyperplasia (BPH)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017041724606N3
Enrollment
76
Registered
2017-05-10
Start date
2016-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute urinary retention. Retention of urine

Interventions

Intervention 1: The control group tamsulosin capsules (0.4 mg) of the drug treatment is given once a day at bedtime in 3 days. Intervention 2: Intervention group Tamsulosin hydrochloride capsules (0.
Treatment - Drugs
The control group tamsulosin capsules (0.4 mg) of the drug treatment is given once a day at bedtime in 3 days
Intervention group Tamsulosin hydrochloride capsules (0.4mg) of Medavadarv once a day at bedtime in 3 days, with slow-release tablets of ISO Surbid Di nitrite 20mg every 12 hours in 3 days

Sponsors

Vice chancellor for researche, Mazandaran University of Medical Siences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with acute urinary retention caused by benign prostatic hypertrophy(BPH). Exclusion criteria: end stage renal disease; diabetes; history of urinary system surgery; malignancy; contraindication of tamsulusin and isosurbid consumption.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Try of urination without a catheter(TWOC). Timepoint: 72 hours after intervention. Method of measurement: Observe of urination without a catheter(TWOC).—

Secondary

MeasureTime frame
Vertigo. Timepoint: 72 hours after intervention. Method of measurement: Observation.;Blood pressure. Timepoint: 72 hours after intervention. Method of measurement: Sphygmomanometer(mmHg).—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamed Aminiahidashti

Mazandaran University of Medical Sciences

hamedaminiahidashti@yahoo.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026